Disclosed herein are processes for preparing certain intermediates useful in the synthesis of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile or a pharmaceutically acceptable salt thereof.

The invention disclosed herein relates to novel Peribysin E analogs of general formula-I. Further the invention provides simple, economical and short synthesis of Peribysin E and its analogs of Formula I, in good yield and purity leading to the identification of more potent cell adhesion inhibitors. ##STR00001##

The invention disclosed herein relates to novel Peribysin E analogs of general formula-I. Further the invention provides simple, economical and short synthesis of Peribysin E and its analogs of Formula I, in good yield and purity leading to the identification of more potent cell adhesion inhibitors. ##STR00001##

Process for preparation of MK-7 type of vitamin K2 is characterized by attaching hexaprenyl chain of “all-trans” configuration to monoprenyl derivative of menadiol following “1+6” synthetic strategy. According to the invention, a-sulfonyl carbanion generated in situ from the protected monoprenyl menadiol of the formula (II), wherein R.sub.1 represents C.sub.1-3-alkyl group, is reacted with hexaprenyl halide of the formula (VII), wherein X represents halogen atom, preferably bromine, both Z′ and Z′ represent H or one of Z′ and Z″ represents H and the other represents phenylsulfonyl group —SO.sub.2Ph in the alkylation reaction. The hexaprenyl halide of formula (VII) is obtained by coupling two triprenyl units in alkylation reaction, with or without separation of the intermediates. ##STR00001##

Process for preparation of MK-7 type of vitamin K2 is characterized by attaching hexaprenyl chain of “all-trans” configuration to monoprenyl derivative of menadiol following “1+6” synthetic strategy. According to the invention, a-sulfonyl carbanion generated in situ from the protected monoprenyl menadiol of the formula (II), wherein R.sub.1 represents C.sub.1-3-alkyl group, is reacted with hexaprenyl halide of the formula (VII), wherein X represents halogen atom, preferably bromine, both Z′ and Z′ represent H or one of Z′ and Z″ represents H and the other represents phenylsulfonyl group —SO.sub.2Ph in the alkylation reaction. The hexaprenyl halide of formula (VII) is obtained by coupling two triprenyl units in alkylation reaction, with or without separation of the intermediates. ##STR00001##

Process for preparation of MK-7 type of vitamin K2 is characterized by attaching hexaprenyl chain of “all-trans” configuration to monoprenyl derivative of menadiol following “1+6” synthetic strategy. According to the invention, a-sulfonyl carbanion generated in situ from the protected monoprenyl menadiol of the formula (II), wherein R.sub.1 represents C.sub.1-3-alkyl group, is reacted with hexaprenyl halide of the formula (VII), wherein X represents halogen atom, preferably bromine, both Z′ and Z′ represent H or one of Z′ and Z″ represents H and the other represents phenylsulfonyl group —SO.sub.2Ph in the alkylation reaction. The hexaprenyl halide of formula (VII) is obtained by coupling two triprenyl units in alkylation reaction, with or without separation of the intermediates. ##STR00001##

A method of preparing 2-alkoxycyclohexanol, a mixture comprising 2-alkoxycyclohexanol obtained via said method, and the use of said mixture for preparing 4-hydroxy-3-alkoxy-benzaldehyde.

A method of preparing 2-alkoxycyclohexanol, a mixture comprising 2-alkoxycyclohexanol obtained via said method, and the use of said mixture for preparing 4-hydroxy-3-alkoxy-benzaldehyde.

The invention relates to a method for producing cyclododecanone (CDON). During the production, contaminated cyclododecane (CDAN) is produced. This can be separated from CDON by distillation (CDAN-containing fraction). The separation of CDAN and impurities such as 13-oxabicyclo [7.3.1]tridecane occurs by crystallizing out CDAN from the CDAN-containing fraction.

The invention relates to a method for producing cyclododecanone (CDON). During the production, contaminated cyclododecane (CDAN) is produced. This can be separated from CDON by distillation (CDAN-containing fraction). The separation of CDAN and impurities such as 13-oxabicyclo [7.3.1]tridecane occurs by crystallizing out CDAN from the CDAN-containing fraction.